Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.730
-0.090 (-4.95%)
At close: Nov 6, 2025, 4:00 PM EST
1.730
0.00 (0.00%)
After-hours: Nov 6, 2025, 8:00 PM EST
Lineage Cell Therapeutics Employees
As of December 31, 2024, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees increased by 2 or 2.67% compared to the previous year.
Employees
77
Change (1Y)
2
Growth (1Y)
2.67%
Revenue / Employee
$141,740
Profits / Employee
-$531,299
Market Cap
395.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 77 | 2 | 2.67% |
| Dec 31, 2023 | 75 | -3 | -3.85% |
| Dec 31, 2022 | 78 | 17 | 27.87% |
| Dec 31, 2021 | 61 | 6 | 10.91% |
| Dec 31, 2020 | 55 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LCTX News
- 4 hours ago - Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 7 days ago - Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Business Wire
- 7 weeks ago - Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Present at September 2025 Investor Conferences - Business Wire
- 2 months ago - Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss - Business Wire
- 3 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire